(Q38248051)

1 September 2017

1 reference

title

The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer (English)

1 reference

evasion of host immune response

1 September 2017

main subject

1 reference

Mads Hald Andersen

2

0 references

Inge Marie Svane

object named as

Inge Marie Svane

series ordinal

3

0 references

author name string

Trine Zeeberg Iversen

series ordinal

1

1 reference

1 September 2017

publication date

13 October 2014

1 reference

Basic and Clinical Pharmacology and Toxicology

1 September 2017

published in

1 reference

1 September 2017

volume

116

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

19-24

1 reference

Distinct sets of genetic alterations in melanoma

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

PI3-kinase subunits are infrequent somatic targets in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Melanoma incidence and mortality in Europe: new estimates, persistent disparities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Completeness of TNM cancer staging for melanoma in the Danish Cancer Registry, 2004-2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Harnessing the immune system for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Expression of tumour-specific antigens underlies cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

The secret ally: immunostimulation by anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

Friends or foes - bipolar effects of the tumour stroma in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12320

21 January 2018

Identifiers

DOI

10.1111/BCPT.12320

1 reference

1 September 2017

1 reference